0001209191-23-054734.txt : 20231108
0001209191-23-054734.hdr.sgml : 20231108
20231108181107
ACCESSION NUMBER: 0001209191-23-054734
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231106
FILED AS OF DATE: 20231108
DATE AS OF CHANGE: 20231108
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Perlich Irene
CENTRAL INDEX KEY: 0001989954
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38853
FILM NUMBER: 231389488
MAIL ADDRESS:
STREET 1: C/O NGM BIOPHARMACEUTICALS, INC.
STREET 2: 333 OYSTER POINT BOULEVARD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NGM BIOPHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001426332
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 333 OYSTER POINT BOULEVARD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-243-5555
MAIL ADDRESS:
STREET 1: 333 OYSTER POINT BOULEVARD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-11-06
0
0001426332
NGM BIOPHARMACEUTICALS INC
NGM
0001989954
Perlich Irene
C/O NGM BIOPHARMACEUTICALS, INC.
333 OYSTER POINT BOULEVARD
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
Principal Accounting Officer
0
Stock Option (Right to Buy)
0.84
2023-11-06
4
A
0
50000
A
2031-03-31
Common Stock
50000
50000
D
Stock Option (Right to Buy)
29.62
2023-11-06
4
D
0
50000
D
2031-03-31
Common Stock
50000
0
D
Stock Option (Right to Buy)
0.84
2023-11-06
4
A
0
35000
A
2032-03-02
Common Stock
35000
35000
D
Stock Option (Right to Buy)
15.20
2023-11-06
4
D
0
35000
D
2032-03-02
Common Stock
35000
0
D
Stock Option (Right to Buy)
0.84
2023-11-06
4
A
0
17500
A
2032-11-03
Common Stock
17500
17500
D
Stock Option (Right to Buy)
5.36
2023-11-06
4
D
0
17500
D
2032-11-03
Common Stock
17500
0
D
The shares subject to the stock option shall vest over a four-year period commencing March 22, 2021, with 1/4th of the shares vesting on March 22, 2022 and 1/48th of the shares vesting monthly thereafter.
Effective November 6, 2023, the Compensation Committee of the Board of Directors of NGM Biopharmaceuticals, Inc. (the "Company") approved a stock option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of a previously-granted stock option in exchange for a new stock option having a lower exercise price of $0.84 per share, which is the closing price of the Company's common stock on November 6, 2023. The reduced exercise price is subject to the relevant retention period and other terms outlined in the applicable stock option repricing notice. All of the other terms of the stock option remained unchanged.
The shares subject to the stock option vest over a four-year period commencing January 1, 2022, with 1/48th of the shares vesting on a monthly basis.
The shares subject to the stock option vest over a two-year period commencing November 4, 2022, with 1/2 of the shares vesting on an annual basis.
/s/ Valerie Pierce, Attorney-in-fact
2023-11-08